Member Info for shareguard

He could still blindside us all by appearing at the launch of Zakari in the morning he was CEO of that was he not.
If he is ousted from that before its even got started maybe for leaking the info we will know for definite its a sacking all in my opinion of course.

LL read this before having the second jab after 4 weeks recommend at least 8 weeks in between jabs

https://www.bbc.co.uk/news/newsbeat-57682233

Thanks to Burble for this post
May I add to Chester's post. For context, I hold a PhD which focussed on the development of antibody therapeutics for melanoma and cervical cancer and still work within the cancer research sector.

Scancell's pipeline is different to other biotechs and is strengthened by the fact that we are not specifically talking about individual products (think individual antibodies, or small-molecule therapeutics). We are talking about adaptable platforms.

Immunobody is a DNA based platform which has the ability to produce high-avidity T-cells to kill infected/cancer cells. Being a DNA based platform it is easy to produce a range of products from - so within a relatively short time a new Immunobody construct targeting a different cancer target or infectious disease target could be generated. Furthermore, the cost of DNA production is small and the product has high stability and a long shelf life meaning high profit margins/low costs.

Moditope is slightly different, but again is a platform based product - this time targeting stress-inducted post-translational modification produced by cancer cells. This has the potential to have low off-target side effects and also target large numbers of cancers.

Avidimab is another product and platform, which can be used to enhance antibodies and their direct cell killing efficiency. This means it can be added to any antibody currently on the market and in development which could improve their effectiveness. This could be licenced to any number of pharma companies developing antibody therapeutics.

Add to all of that we have the anti-glycan monoclonal antibodies. These are more stand along products on their own and have specific functions/targets for each one. These could be valuable as single entity products or as a package.

As a pipeline, what stands out for Scancell vs. other pharma/biotech start ups is the fact that the bulk of their products are platforms. This means they have almost infinite scope to generate new therapies once the platform is proved to work. So whilst there is risk with any product and platforms are no different, once one of these makes it through trials to the clinic, the platform is validated and so any number of 'flavours' of that platform, targeting any number of targets becomes available. Covidity validates Immunobody and Avidimab and a new needle-free delivery system in a single set of trials. SCIB1 trials validates immunobody in cancer and the new Moditope trial (esp. phase 2) is 4 hard to treat cancer trials in one.

If you compare this to a lot of biotechs/pharma they put all their eggs in a single basket with a single product. If that fails, it's back to the drawing board. If it works, many companies will buy that product and incorporate it into their own portfolio. Scancell platforms if validated could be v.v.valuable especially if licenced out to any number of players in the field of infectious disease or oncology.
Recommend (62

WTP nice one i can see the Scancell jobs but what about the one through Yoh agency that the link takes you too.
Could this be for Zakari and scancell spinning out AvidiMab.
Lets pick the bones out of the Job advert based in Oxford start up biotech company with recent multi-million investment.
Then look at the avidiMab peer reviewed paper published on the 12 June 2020 some of which below. said before this is what got our Americans interest

Yoh Scientific is working with a Start-up Biotech which aspire to be the world leaders in the development of novel antibody therapeutics for the treatment of inflammatory diseases., and in doing so, change patients’ lives. With a recent multi-million pound investment they are now recruiting for a Senior Scientist to join their team, and return can offer broad exposure to innovative therapeutic programmes, significant opportunities for career development and a supportive, driven and ambitious team environment.

For this role, you should be excited about working in a small, dynamic team; always keen to get involved; and be a team player. The position represents an excellent opportunity for someone looking to take on responsibility in the discovery of new antibody drugs and establishment of novel methodologies. Applicants should have laboratory research experience particularly in the areas of antibody discovery using B cell techniques (e.g. B cell culture and/or single B cell screening), cellular biology and molecular biology. As part of this role, you will work on novel antibody discovery programmes, establish high-throughput B cell screening methodologies, conduct cellular assay

12 June 2020

Scancell Holdings plc

("Scancell" or the "Company")

Peer reviewed publication highlights potential of AvidiMab™ to enhance the potency of any therapeutic antibody

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to note the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR), entitled: "Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement".1

The paper describes how Scancell's AvidiMab™ modifications to the constant region (Fc) of any antibody can improve avidity, or strength of interaction, between the antibody and its target antigen, thereby improving the antibody's potential therapeutic properties. This same modification also has demonstrated that Scancell's own tumour-associated glycan (TaG) antibodies can directly kill tumour cells.



In recent years, antibodies have become the best-selling drugs in the pharmaceutical market and have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. The global therapeutic monoclonal antibody market is estimated to be US$150 billion in 2019 and predicte

Zakari is a Hebrew name, and the name Zakari means "the Lord recalled".
The Lord recalled Scancell to form Zakari list on Nasdaq raising billions and cure the world of cancer bring on Saint Lindy.
I can dream for something like that..

TF also on BBC website

https://www.bbc.co.uk/news/science-environment-57548531

"The prime minister is said to want to build on the success of the UK's coronavirus vaccine programme and apply it to other areas. These include developing technology to reach net zero carbon emissions and curing cancer rather than simply treating it."

Didn't innaco have the ear of a DT journalist.

£1/£4 prefer safestocks £15 but hey £1 would make me very happy could close selling on ebay rodders for good.......:):)

The job advert said enough

Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine in melanoma patients and also progressing to a first-in-human study of its Moditope® vaccine in patients with advanced solid tumours.
Dont recall the rns saying the phase 2 trial started of Immunobody either but clearly states Moditope progressing......

Re-posted below.

Excerpt from one of the jobs, this will do for me.....

Scancell, is an AIM listed biotech company, developing novel immunotherapies for the treatment of cancer and infectious disease, with facilities on the Oxford Science Park and at Nottingham University.Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine in melanoma patients and also progressing to a first-in-human study of its Moditope® vaccine in patients with advanced solid tumours. The successful candidates will be integrated into a multidisciplinary team involved in the development of the ImmunoBody® and Moditope® cancer vaccine platforms, the AvidiMabTM therapeutic antibody platform, as well as the development of a second-generation COVID-19 vaccine.

Excerpt from one of the jobs, this will do for me.....

Scancell, is an AIM listed biotech company, developing novel immunotherapies for the treatment of cancer and infectious disease, with facilities on the Oxford Science Park and at Nottingham University.Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine in melanoma patients and also progressing to a first-in-human study of its Moditope® vaccine in patients with advanced solid tumours. The successful candidates will be integrated into a multidisciplinary team involved in the development of the ImmunoBody® and Moditope® cancer vaccine platforms, the AvidiMabTM therapeutic antibody platform, as well as the development of a second-generation COVID-19 vaccine.

You are right TF and Scancell working with Notts uni on a delivery system but its inconceivable for me in that John Chiplin is chairman of N4p and Scancell one as a delivery system and the other a vaccine that the two are not linked in some way.
It would not be beyond probabilities that Scancell have more than one delivery method on trial anyway i have money on both horses.....kerching

https://www.lse.co.uk/rns/N4P/operations-update-v8ibirolqsxiej7.html

Collaborations



The Company is pleased to announce that it has entered into two Material Transfer Agreements ("MTAs") to assess how well Nuvec® can bind and be optimised for transfection with two different proprietary plasmids. The first is with a major international company working in the gene therapy space and the second is a pharmaceutical company developing its own proprietary vaccine for Covid-19 using a DNA plasmid. Each MTA is subject to certain confidentiality clauses as to the extent of detail that may be disclosed, including the name of the other party. Subject to the results of the work undertaken these MTAs represent a significant first step towards more formal collaborations. In addition to the two MTAs signed, the Company continues in dialogue with other parties with a view to entering into more MTAs.

Ok i am in both N4p and scancell one of the companies above may be Scancell reason --- the two companies are closely linked John Chiplin. Check them out.

https://www.bbc.co.uk/news/uk-england-london-57080188

Investigators found inadequate signage and no mechanisms to monitor driver alertness or to automatically apply the brakes when the tram was travelling too fast.

Both have since been introduced, but, that is too late for Jean and the other families. They want to know why safeguards were not in place.

Maybe some coverage of our tech in the press when inquest starts.

Its rare but only a 6 years ago in Scotland a dustbin wagon veered onto the pavement mowing down several people killing 6 in Glasgow the driver was seen slumped over the steering wheel before the crash.
DMS with controlled stop and automatic braking may have helped in this instance to save lives.
https://www.theguardian.com/uk-news/2014/dec/23/glasgow-bin-lorry-crash-couple-granddaughter-six-dead-named

Dont call Techie every time he posts the price rises keep posting mate you are doing a good job.

Crumbs you must be Father Christmas then Lol.

https://www.bbc.co.uk/news/business-56332388 interesting read like these bits.

According to data from Acumen Research and Consulting, the semi and fully autonomous truck market is expected to reach approximately $88bn (£64bn; €74bn) by 2027, growing at a compound annual growth rate of 10.1% between 2020 and 2027.

For the foreseeable future, he explains, even autonomous trucks will still have "drivers" in the cab as a safety measure, to be on hand in case of mechanical problems or even speak to police in the event of an incident on the highway.

"It's not clear at all now whether there will even be displacement," he says. "You need the back-up driver. Within the next five or 10 years, it seems reasonable to expect some movement towards autonomy, but with a co-pilot. In my view, it's like a long-haul flight. The plane can be put on autopilot, but you still have the pilot."

Plenty of opportunities for seeing machines here.

No TD we should be hoovering shares up while price is low tho agree price should be hovering above 14p

I dont agree i think it means in the context a one stop jab how on earth can a notts uni make the vaccine wide spread when europe with all the funds struggle to do just that.

I think Alex and max were twins with different views but Alex suddenly thought he was max Lol.

Mmm how do you propose to get there with travel restrictions?